Vor Biopharma Inc. SEC Filings

Reprogrammed Interchange LLC and Reid Hoffman reported multiple open-market sales of Vor Biopharma (VOR) common stock in September 2025. The filing discloses three non-derivative sales: 284,805 shares sold on 09/11/2025 at a weighted average price of $1.8308, 300,000 shares sold on 09/12/2025 at $1.7541, and 400,000 shares sold on 09/15/2025 at $1.6408. Following the transactions, Reprogrammed held 33,228,487 shares on a direct basis. The form clarifies the prices are weighted averages from multiple trades and states that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed due to shared control, but he disclaims beneficial ownership except for his pecuniary interest.

Amendment No. 3 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman reduced their combined beneficial stake in Vor BioPharma Inc. through multiple open-market sales. The reporting persons now report beneficial ownership of 33,928,487 shares (26.8% of the class). The amendment details sales from August 25 through September 11, 2025, that together total 5,045,614 shares sold in the referenced transactions, executed at weighted average prices mostly around $1.82–$2.12 per share. The filing states the sales were in open market transactions and that there are no related contracts or arrangements with respect to the issuer’s securities.

The amendment is a disclosure of significant share disposition by the reporting persons and confirms continued shared voting and dispositive power over the reported shares.

Vor Biopharma insiders sold a substantial block of common stock over three days. Reprogrammed Interchange LLC reported three dispositions totaling 1,263,647 shares sold in multiple trades at weighted-average prices of $1.9897, $2.0004 and $1.8151. Reported post-transaction beneficial holdings held by Reprogrammed decreased from 35,012,518 to 34,213,292 shares across the reported transactions. The filing notes these shares are held by Reprogrammed Interchange LLC and that Reid Hoffman may be deemed an indirect beneficial owner by virtue of shared control and pecuniary interest, while disclaiming beneficial ownership except to the extent of any pecuniary interest.

Vor Biopharma Inc. (VOR) reported a non-derivative/derivative reporting event showing a 60,000-share stock option granted on 09/08/2025 with a $1.98 exercise price. The option is held for the benefit of RA Capital funds and is reported as indirect ownership of 60,000 shares, subject to monthly vesting in 36 equal installments beginning 09/08/2025 and with an indicated exercisability/expiration date of 09/07/2035. Reporting entities include RA Capital Management, L.P., RA Capital Healthcare Fund, RA Capital Nexus Fund, and individuals Dr. Peter Kolchinsky and Rajeev Shah, who disclaim beneficial ownership except for pecuniary interests. Ms. Sarah Reed, General Counsel of the Adviser, serves on Vor's board and will hold the option for the benefit of the funds under an arrangement requiring turnover of any net proceeds to offset advisory fees.

Vor Biopharma Inc. director Sarah Burgess Reed was granted a stock option on 09/08/2025 to purchase 60,000 shares of common stock at an exercise price of $1.98 per share. The option vests in 36 equal monthly installments beginning on the grant date and is exercisable through 09/07/2035. The filing notes Ms. Reed holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., and she disclaims beneficial ownership because any net proceeds will be turned over to the adviser to offset advisory fees. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.

Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.

Vor Biopharma Inc. (VOR) filing an initial Form 3 by reporting person Sarah Burgess Reed shows she is identified as a director and that, as of the event date 08/27/2025, no securities are beneficially owned by her. The filing is marked as an initial statement and was signed on 09/08/2025 by an attorney-in-fact, Sherell Bacchas.

This is a routine Section 16 disclosure showing the reporting relationship and a declaration of zero ownership of the issuer's equity. The form does not report any derivative holdings, purchases, sales, or other transactions and contains no financial tables or material transaction details.

Vor Biopharma Inc. (VOR) Form 4: Reprogrammed Interchange LLC and Reid Hoffman reported a series of open-market sales of common stock in early September 2025. Reprogrammed sold 554,612 shares on 09/03/2025 at a weighted average price of $1.9961, 453,016 shares on 09/04/2025 at $1.9285, and 400,000 shares on 09/05/2025 at $1.9682. Following these transactions, Reprogrammed's reported beneficial ownership decreased from 36,329,955 shares to 35,476,939 shares. The filing notes that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed but disclaims ownership except for pecuniary interest.

Vor Biopharma Inc. Form 144 notifies the market that a person identified as Audrey Skillern intends to sell 23,000,000 common shares on or about 09/03/2025 on NASDAQ. The filing lists an aggregate market value of $46,115,000 for the shares and reports 126,683,111 shares outstanding for the issuer.

The shares were acquired from the company in a private placement on 12/26/2024 and fully paid in cash on that date. The filer reports no securities sold in the past three months. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.